OVERVIEW

Cardiovascular Innovations 2020 is organized by AcademicCME.

Start Date: 09-05-2019
Expires: 09-04-2020

Accreditation:
AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 CreditTM.

Description:
This continuing education program will highlight recent advances in the treatment and management of breast cancer, with a focus on HER2-targeted therapy. The expert faculty will review the current treatment landscape for both early stage and metastatic breast cancer. Recent clinical trial data of emerged and emerging agents, particularly best practices for optimizing HER2-targeted therapy continuing into the adjuvant setting, will be reviewed and clinical relevance debated. At the conclusion of this CME program, learners will better understand the clinical implications of recent clinical trial data, to improve outcomes and quality of life in patients with breast cancer.

Objectives:
• Discuss the biologic and molecular pathogenesis of breast cancer to understand how to develop strategies for early intervention and effective diagnosis of patients
• Assess clinical trial data of novel pharmaceuticals for the treatment of patients with breast cancer
• Work with the interprofessional team to develop individualized treatment strategies to achieve optimal outcomes in patients with breast cancer

Additional details will be posted as soon as information is available